Melissa Azoulay1, Jennifer Shah2, Erqi Pollom2, Scott G Soltys2. 1. Department of Radiation Oncology, McGill University Health Centre, Glen site, 1001 Decarie, Montreal, Quebec, H4A 3J4, Canada. melissa.azoulay@mcgill.ca. 2. Department of Radiation Oncology, Stanford University Cancer Center, 875 Blake Wilbur Dr., Stanford, CA, 94305, USA.
Abstract
PURPOSE OF REVIEW: Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed GBM. RECENT FINDINGS: Investigators have explored alternative radiotherapy strategies that shorten treatment duration with the goal of similar or improved survival while minimizing toxicity. HFRT over 1-3 weeks is already a standard of care for patients with advanced age or poor performance status. For young patients with good performance status, HFRT holds the promise of radiobiologically escalating the dose and potentially improving local control while maintaining quality of life. Through the use of shorter radiotherapy fractionation regimens coupled with novel systemic agents, improved outcomes for patients with GBM may be achieved.
PURPOSE OF REVIEW: Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed GBM. RECENT FINDINGS: Investigators have explored alternative radiotherapy strategies that shorten treatment duration with the goal of similar or improved survival while minimizing toxicity. HFRT over 1-3 weeks is already a standard of care for patients with advanced age or poor performance status. For young patients with good performance status, HFRT holds the promise of radiobiologically escalating the dose and potentially improving local control while maintaining quality of life. Through the use of shorter radiotherapy fractionation regimens coupled with novel systemic agents, improved outcomes for patients with GBM may be achieved.
Authors: Erqi L Pollom; Dylann Fujimoto; Jacob Wynne; Kira Seiger; Leslie A Modlin; Lisa R Jacobs; Melissa Azoulay; Rie von Eyben; Laurie Tupper; Iris C Gibbs; Steven L Hancock; Gordon Li; Steven D Chang; John R Adler; Griffith R Harsh; Ciara Harraher; Seema Nagpal; Reena P Thomas; Lawrence D Recht; Clara Y H Choi; Scott G Soltys Journal: Int J Radiat Oncol Biol Phys Date: 2017-02-07 Impact factor: 7.038
Authors: Changhu Chen; Denise Damek; Laurie E Gaspar; Allen Waziri; Kevin Lillehei; B K Kleinschmidt-DeMasters; Monica Robischon; Kelly Stuhr; Kyle E Rusthoven; Brian D Kavanagh Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-06 Impact factor: 7.038
Authors: W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth Journal: J Clin Oncol Date: 2004-03-29 Impact factor: 44.544
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: M P Mehta; J Masciopinto; J Rozental; A Levin; R Chappell; K Bastin; J Miles; P Turski; S Kubsad; T Mackie Journal: Int J Radiat Oncol Biol Phys Date: 1994-10-15 Impact factor: 7.038
Authors: Nathan S Floyd; Shiao Y Woo; Bin S Teh; Charlotte Prado; Wei-Yuan Mai; Todd Trask; Philip L Gildenberg; Paul Holoye; Mark E Augspurger; L Steven Carpenter; Hsin H Lu; J Kam Chiu; Walter H Grant; E Brian Butler Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-01 Impact factor: 7.038
Authors: Charles P Hinzman; Janet E Baulch; Khyati Y Mehta; Michael Girgis; Shivani Bansal; Kirandeep Gill; Yaoxiang Li; Charles L Limoli; Amrita K Cheema Journal: Sci Rep Date: 2019-07-01 Impact factor: 4.379